Study finds AI chatbot significantly improve symptoms for those suffering from major depressive disorder (MDD), generalized ...

Neuronetics' strategic acquisitions, including Greenbrook, and FDA approvals are expected to drive revenue growth. See why ...

A novel PET imaging approach can effectively quantify a key enzyme associated with brain inflammation, according to research ...

The research team believes that AI treatment chatbots have the potential to provide large-scale customized mental health ...

Relmada Therapeutics pivots to NDV-01 for bladder cancer & Sepranolone for Tourette's. Phase 2 results expected April 2025.

The updated consolidated financial statements for the year and three months ending December 31, 2024 are attached to this press release and fully reflect the accounting updates. The Company also filed ...

A groundbreaking clinical trial on AI therapy chatbots shows significant reductions in depression, anxiety, and disordered ...

Recognizing how persistent depressive disorder manifests and plays out in the lives of individuals is the first step in ...

Dartmouth researchers conducted the first clinical trial of a therapy chatbot powered by generative AI and found that the software resulted in significant improvements in participants' symptoms, ...

Study participants on average experienced statistically significant improvements in their symptoms after using Therabot for eight weeks. The trial consisted of 106 people from across the United States ...

The FDA has cleared Magstim Horizon 3.0 TMS Therapy System as an adjunct for the treatment of MDD in adolescent patients aged 15 to 21 years.

Patients with COPD plus a depression/anxiety disorder had poorer scores related to disease burden and health-related quality of life, according to data published in Chronic Obstructive Pulmonary ...